tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Sports

tanzania times : Latest News and In-depth Analysis
HomeSports
Sports

Mar 18, 2025

Optoma Introduces the Ultimate Display Management Solution

TAIPEI,March 18,2025-- The widely acclaimed Optoma Management Suite (OMS),an innovative display device management system highly praised by IT administrators,has undergone a comprehensive upgrade in 20

All News

Full Truck Alliance Co. Ltd. to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on Wednesday, March 5, 2025

Earnings Call Scheduled for 7:00 A.M. U.S. ET on March 5,2025 GUIYANG,China,Feb. 14,2025-- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM),a leading digital freig

Feb 17, 2025

Sports

First Drone Show by Soiree Rooftop Bar, Lights Up Surabaya's Skyline

SURABAYA,Indonesia,Feb. 14,2025--A night of enchantment and cultural splendor unfolded at Soirée Rooftop Bar as The 1st Drone Show & Lunar Party illuminated the Surabaya skyline in a breath

Feb 17, 2025

Sports

ATxEnterprise 2025 Celebrates Five Years of Powering Enterprise Technology, Cybersecurity, and Digital Transformation

SINGAPORE,Feb. 14,2025-- ATxEnterprise (ATxE) 2025,a flagship event of Asia Tech x Singapore (ATxSG),returns for its fifth year,providing a strategic platform for enterprises,governments,and technolo

Feb 17, 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi

Feb 14, 2025

Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa

The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial.

Feb 14, 2025

Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium

CHENGDU,China,Feb. 13,2025-- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025,to be held in San Francisco,USA,from Feb. 13-15,2025,Sichuan Kelun-Biotech Bi

Feb 14, 2025

1 ... 63 64 65 66 67 68 69 ... 107